Search

Your search keyword '"Thomas Farge"' showing total 16 results
Start Over Author "Thomas Farge" Publisher american association for cancer research (aacr)
16 results on '"Thomas Farge"'

1. Supplementary Table S3 from Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia

Author

Jean-Emmanuel Sarry, François Vergez, Christian Récher, Jérome Tamburini, Carine Joffre, Tony Kaoma, Francisco Azuaje, Nathalie Nicot, Jean-Charles Portais, Floriant Bellvert, Nathalie Bonnefoy, Mathilde Gotanègre, Camille Laurent, Charlotte Syrykh, Muriel Picard, Massimiliano Bardotti, Sarah Gandarillas, Latifa Jarrou, Clément Larrue, Fetta Mazed, Marie Sabatier, Lucille Stuani, Claudie Bosc, Thomas Farge, Pierre-Luc Mouchel, Mohsen Hosseini, Fabienne de Toni, Ryan Gwilliam, Estelle Saland, Marie-Laure Nicolau-Travers, Margherita Ghisi, Emeline Boet, and Nesrine Aroua

Abstract

Table S3

Published
2023

2. Supplementary Table S6 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

HIGH CD36 gene signature generated from upregulated genes in AML patients that express the most CD36 mRNA compared to that of the lowest expression of CD36 in TCGA cohort.

Published
2023

3. Supplementary Table S7 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

Summary of all GSEA data identified in AraC- versus PBS-treated AML cells in PDX and LOW versus HIGH Responder to AraC in PDX.

Published
2023

4. Supplementary Table S6 from Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia

Author

Jean-Emmanuel Sarry, François Vergez, Christian Récher, Jérome Tamburini, Carine Joffre, Tony Kaoma, Francisco Azuaje, Nathalie Nicot, Jean-Charles Portais, Floriant Bellvert, Nathalie Bonnefoy, Mathilde Gotanègre, Camille Laurent, Charlotte Syrykh, Muriel Picard, Massimiliano Bardotti, Sarah Gandarillas, Latifa Jarrou, Clément Larrue, Fetta Mazed, Marie Sabatier, Lucille Stuani, Claudie Bosc, Thomas Farge, Pierre-Luc Mouchel, Mohsen Hosseini, Fabienne de Toni, Ryan Gwilliam, Estelle Saland, Marie-Laure Nicolau-Travers, Margherita Ghisi, Emeline Boet, and Nesrine Aroua

Abstract

Table S6

Published
2023

5. Supplementary Table S1 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

(1) Clinical characteristics of 27 AML patients used in this study for engraftment in NSG mice, including the 25 ones treated in vivo with 60 mg/kg/d cytarabine (AraC) for 5 days. (2) Clinical and mutational characteristics of AML cell lines used in this study.

Published
2023

6. Supplementary Table S5 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

Up- and down-regulated genes in AML patients that have the lower response (LowR) to AraC in vivo in NSG mice compared to high responder (HighR) to AraC in vivo using PDX assay.

Published
2023

7. Supplementary Table S5 from Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia

Author

Jean-Emmanuel Sarry, François Vergez, Christian Récher, Jérome Tamburini, Carine Joffre, Tony Kaoma, Francisco Azuaje, Nathalie Nicot, Jean-Charles Portais, Floriant Bellvert, Nathalie Bonnefoy, Mathilde Gotanègre, Camille Laurent, Charlotte Syrykh, Muriel Picard, Massimiliano Bardotti, Sarah Gandarillas, Latifa Jarrou, Clément Larrue, Fetta Mazed, Marie Sabatier, Lucille Stuani, Claudie Bosc, Thomas Farge, Pierre-Luc Mouchel, Mohsen Hosseini, Fabienne de Toni, Ryan Gwilliam, Estelle Saland, Marie-Laure Nicolau-Travers, Margherita Ghisi, Emeline Boet, and Nesrine Aroua

Abstract

Table S5

Published
2023

8. Supplementary Table S2 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

Determination of LICs frequency in bone marrow and spleen from AraC- or PBS-treated AML-xenografted NSG mice using in vivo limiting dilution assay.

Published
2023

9. Supplementary Table S4 from Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia

Author

Jean-Emmanuel Sarry, François Vergez, Christian Récher, Jérome Tamburini, Carine Joffre, Tony Kaoma, Francisco Azuaje, Nathalie Nicot, Jean-Charles Portais, Floriant Bellvert, Nathalie Bonnefoy, Mathilde Gotanègre, Camille Laurent, Charlotte Syrykh, Muriel Picard, Massimiliano Bardotti, Sarah Gandarillas, Latifa Jarrou, Clément Larrue, Fetta Mazed, Marie Sabatier, Lucille Stuani, Claudie Bosc, Thomas Farge, Pierre-Luc Mouchel, Mohsen Hosseini, Fabienne de Toni, Ryan Gwilliam, Estelle Saland, Marie-Laure Nicolau-Travers, Margherita Ghisi, Emeline Boet, and Nesrine Aroua

Abstract

Table S4

Published
2023

10. Supplementary Table S3 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

(1) Gene signatures of AraC residual AML blasts in vivo from three AML patients xenografted and treated with AraC. (2) Functional analyses of up-regulated genes of AraC residual AML blasts in vivo. (3) Functional analyses of down-regulated genes of AraC residual AML blasts in vivo. (4) Prognostic analysis of the up- and down- regulated gene signatures of AraC-residual AML blasts in vivo in three independently published cohorts of AML patients.

Published
2023

11. Supplementary Methods and Supplementary Figures 1 through 18 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

Supplementary Methods. Supplementary Figure S1. Clinical distributions of AML patients from TUH and 3 independent patient cohorts. Supplementary Figure S2. In vivo treatment with 60 mg/kg/d of cytarabine (AraC) given daily for 5 days induces a significant reduction of the total cell tumor burden in AML-engrafted mice. Supplementary Figure S3. In vivo cytarabine (AraC) treatment induces significant but heterogeneous response in bone marrow and spleen of AML-xenografted NSG mice. Supplementary Figure S4. Comparative analysis of the in vivo response to cytarabine (AraC) with clinicobiological data of AML patients. Supplementary Figure S5. In vivo cytarabine (AraC) treatment induces changes in CD34+/-CD38+/- phenotypes in AML-engrafted mice. Supplementary Figure S6. In vivo cytarabine (AraC) chemotherapy treatment leads to reduction of the absolute number of human CD34+CD38+/- populations in AML. Supplementary figure S7. No enrichment in G0 quiescent cells was observed in mice treated with sublethal dose of cytarabine (AraC) for 5 days in vivo. Supplementary figure S8. Mitochondrial and energetic features of LOW (KG1, KG1a, U937) and HIGH (MOLM14, MV4-11, HL60) OXPHOS AML cell lines. Supplementary figure S9. Functional analysis of the transcriptomes of LOW (KG1a, U937) versus HIGH (MOLM14, HL60) OXPHOS AML cell lines untreated or treated with metformin. Supplementary figure S10. AML cells surviving after cytarabine (AraC) treatment are resistant to chemotherapies and are pre-existing CD36+CD44+ phenotype with an increased oxidative metabolism. Supplementary figure S11. Culture in galactose induces energetic shift of LOW OXPHOS AML U937 cells toward HIGH OXPHOS state, leading to cytarabine (AraC) resistance in AML. Supplementary figure S12. Energetic shift of mtDNA-depleted Rho0 MOLM14 cells toward LOW OXPHOS state induces AraC sensitivity. Supplementary figure S13. Electron Transfer Chain Complex I inhibition by Phenformin (Phenf) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S14. Electron Transfer Chain Complex I inhibition by Metformin (Met) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S15. Electron Transfer Chain Complex I inhibition by Rotenone (Rot) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S16. Electron Transfer Chain Complex III inhibition by Antimycin A (AntiA) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S17. Electron Transfer Chain Complex III inhibition by Atovaquone (ATQ) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S18. Working model of the resistance to AraC in vivo.

Published
2023

12. Supplementary Table S4 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

(1) HIGH OXPHOS gene signature generated from HIGH versus LOW OXPHOS AML cell lines untreated or treated with metformin. (2) Functional analysis of upregulated genes encoding for mitochondrial proteins in untreated HIGH versus LOW OXPHOS AML cell lines.

Published
2023

13. Supplementary Data from Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia

Author

Jean-Emmanuel Sarry, Christian Récher, Guillaume Bossis, Marc Piechaczyk, Mathilde Gotanègre, Pierre Luc Mouchel, Marie Sabatier, Clément Larrue, Latifa Jarrou, Sonia Zaghdoudi, Véronique Guyonnet-Dupérat, Estelle Saland, Thomas Farge, Claudie Bosc, Nesrine Aroua, Hamid Reza Rezvani, and Mohsen Hosseini

Abstract

Supplementary Table 1 Clinical and mutational features of AML patient samples used in this study

Published
2023

14. Supplementary Figures from Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia

Author

Jean-Emmanuel Sarry, Christian Récher, Guillaume Bossis, Marc Piechaczyk, Mathilde Gotanègre, Pierre Luc Mouchel, Marie Sabatier, Clément Larrue, Latifa Jarrou, Sonia Zaghdoudi, Véronique Guyonnet-Dupérat, Estelle Saland, Thomas Farge, Claudie Bosc, Nesrine Aroua, Hamid Reza Rezvani, and Mohsen Hosseini

Abstract

Supplementary Figures 1-7

Published
2023

15. Supplementary Methods from Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia

Author

Jean-Emmanuel Sarry, Christian Récher, Guillaume Bossis, Marc Piechaczyk, Mathilde Gotanègre, Pierre Luc Mouchel, Marie Sabatier, Clément Larrue, Latifa Jarrou, Sonia Zaghdoudi, Véronique Guyonnet-Dupérat, Estelle Saland, Thomas Farge, Claudie Bosc, Nesrine Aroua, Hamid Reza Rezvani, and Mohsen Hosseini

Abstract

Supplementary Methods

Published
2023

16. Abstract B06: Studying cytarabine resistance through PDX models in acute myeloid leukemia

Author

Thomas Farge

Subjects
Cancer Research, business.industry, Cancer, Myeloid leukemia, Context (language use), Gene signature, Cell cycle, medicine.disease, Immune system, Oncology, Immunology, medicine, Cancer research, Cytarabine, Stem cell, business, medicine.drug
Abstract

The major therapeutic barrier in acute myeloid leukemia (AML) is chemotherapy resistance. AML cells resistant to conventional chemotherapy targeting DNA synthesis are thought to be enriched in quiescent leukemic stem cells (LSCs). In order to better understand chemotherapy resistance in AML, we analyzed the response to cytarabine (AraC) through patient-derived xenograft (PDX) models with 20 primary AML patient specimens from two clinical sites and in the context of a French “Innovative models initiative” (IMODI) program. After confirming AML engraftment, highly immunodeficient NOD/LtSz-scid IL2Rγc null (NSG) mice were treated with AraC administered IP for 5 days as a single agent at 60 mg/kg daily, which correlates with human dosing. In all mice treated with this regimen, there was a significant but variable cytoreductive effect (4- to 46-fold reduction of tumor cell burden; 2- to 13-fold induction of apoptosis) at 3 days post-treatment. This in vivo AraC response in PDX models has been compared to clinicobiological data of their matched patients (including overall survival, FAB classification, and age at diagnosis). Furthermore, residual leukemic cells (RLCs), surviving after in vivo AraC treatment, have been characterized for their cell surface phenotype, stem cell frequency, cell cycle and metabolic status. Gene expression of RLCs from three different PDX models showed an enrichment of genes involved in inflammatory, immune and stress/ROS responses. When tested in three independent cohorts of AML patients (Verhaak et al. 2009; TGCA. 2011; Metzeler et al. 2011), the down-regulated gene signature is associated with an unfavorable prognosis in patients treated with intensive chemotherapy. Altogether, these results suggest a novel model of AraC chemotherapy resistance uncovering the control of the oxidative and mitochondrial energy metabolism in vivo and the relevance of PDX models for clinical investigations and new preclinical drug assessment. Further studies of the role of immune and stromal microenvironment will be assessed in this model to extend our findings in a more relevant setting. Citation Format: Thomas Farge{Authors}. Studying cytarabine resistance through PDX models in acute myeloid leukemia. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr B06.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results